Key result
Renal denervation is linked to a ~14-mmHg drop in systolic BP at 12 months.
Why the study?
Does catheter-based renal denervation improve office blood pressure, time in therapeutic range, and medication burden over 12 months in hypertensive patients in routine clinical practice?
Cohort (n=142)
Yes
Does catheter-based renal denervation improve office blood pressure, time in therapeutic range, and medication burden over 12 months in hypertensive patients in routine clinical practice?
In a real-world Taiwanese registry, catheter-based renal denervation provided durable 12-month blood pressure reductions and improved time in therapeutic range while reducing antihypertensive medication burden without major complications.
Answers are grounded in this paper and cite their sources.
Supports RDN for BP control in real-world Asian patients; extends registry data but leaves open randomized confirmation.
The extent to which renal denervation (RDN) improves sustained blood pressure (BP) control, medication burden, and time in therapeutic range (TTR) in real-world Asian populations remains incompletely defined. We analyzed data from a prospective, nationwide, multi-center registry enrolling consecutive hypertensive patients undergoing catheter-based RDN at seven hospitals in Taiwan. Office BP, medication burden, and TTR were assessed over 12 months. Among 142 patients (mean age 59.4 ± 14.7 years; 68.3% men), baseline BP was 155.2 ± 24.1/84.1 ± 14.2 mmHg with a mean medication burden of 2.28 ± 1.19. BP decreased significantly and was sustained throughout follow-up. At 12 months, BP decreased by 13.9 ± 25.2/6.3 ± 20.5 mmHg from baseline ( p < 0.01), while medication burden decreased by 0.76 ± 1.26 ( p < 0.01). For BP < 140/90 mmHg, TTR increased from 27.7% at baseline to 47.5% at 12 months ( p < 0.01); for BP < 130/80 mmHg, TTR increased from 12.8% to 25.9% ( p < 0.01). No major procedure-related complications were observed. In this nationwide real-world registry, RDN was associated with durable BP reduction, improved time in therapeutic range, and reduced medication burden over 12 months. These findings suggest that RDN may not only lower BP but also enhance sustained BP control while reducing antihypertensive medication burden in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) conducted a cohort in Hypertension (n=142). Catheter-based renal denervation (RDN) was evaluated on Office blood pressure, medication burden, and time in therapeutic range (TTR) at 12 months (MD -13.9/-6.3 mmHg, p=<0.01). Catheter-based RDN reduced office BP by 13.9/6.3 mmHg, lowered medication burden by 0.76, and increased TTR (<140/90 mmHg) from 27.7% to 47.5% at 12 months (all p<0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: